Monica Gandhi MD, MPH is Professor of Medicine and Associate Division Chief (Clinical Operations/ Education) of the Division of HIV, Infectious Diseases, and Global Medicine at UCSF/ San Francisco General Hospital. She also serves as the Director of the UCSF Center for AIDS Research (CFAR) and the Medical director of the HIV Clinic at SFGH ("Ward 86"). Dr. Gandhi completed her M.D. at Harvard Medical School and then came to UCSF in 1996 for residency training in Internal Medicine. After her residency, Dr. Gandhi completed a fellowship in Infectious Diseases and a postdoctoral fellowship at the Center for AIDS Prevention Studies, both at UCSF. She also obtained a Masters in Public Health from Berkeley in 2001 with a focus on Epidemiology and Biostatistics.
Experience
–present
Professor of Medicine, Division of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco
Education
2001
University of California, Berkeley, MPH
1999
University of California, San Francisco, Infectious Diseases Fellowship
1996
University of California, San Francisco, Residency
1996
Harvard Medical School, M.D.
Publications
2019
Antiretroviral concentrations in hair strongly predict virologic response in a large HIV treatment-naive clinical trial, Clinical Infectious Diseases
2019
Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cut-Off for a Point-of-Care Test, JAIDS
2019
Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a PrEP demonstration project, AIDS
2019
RAPID ART: High virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population, AIDS
2018
Degree of Housing Instability Shows Independent “Dose-Response” with Virologic Suppression Rates among People Living with HIV, Open Forum Infectious Diseases
2018
Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence, The Lancet
2016
HIV Pre-Exposure Prophylaxis for Women, Journal of Virus Eradication
Grants and Contracts
2020
Objective measures of adherence for later-stage ART failure in resource limited settings
Role:
PD/PI
Funding Source:
National Institute of Allergy and Infectious Diseases
2019
Simplifying HIV Treatment and Monitoring (STREAM2): Point-of-Care Urine Tenofovir Adherence and Viral Load Testing to Improve HIV Outcomes in
Role:
PD/PI
Funding Source:
National Institute of Allergy and Infectious Diseases
2018
Point-of-care Urine Monitoring of Adherence (PUMA): Testing a Real-Time Urine Assay of Tenofovir in PrEP
Role:
PD/PI
Funding Source:
National Institute of Allergy and Infectious Diseases
2017
Hair Extensions;: Using Hair Levels to Interpret Adherence, Effectiveness and Pharmacokinetics with Real-World Oral PrEP, the Vaginal Ring, and
Role:
PD/PI
Funding Source:
National Institute of Allergy and Infectious Diseases
1997
UCSF-GIVI Center for AIDS Research (CFAR)
Role:
PD/PI
Funding Source:
National Institute of Allergy and Infectious Diseases